A randomised, open-label, multicentre, Phase III trial of in vivo purging with anti-CD38 (Daratumumab) to enhance myeloma autografting (IPANEMA)

  • Hodgkinson, Andrea (Co-Investigator)
  • Siddique, Shamyla (Co-Investigator)
  • Gates, Simon (Co-Investigator)
  • Craddock, Charles (Principal Investigator)

Project Details

Short titleA randomised, open-label, multicentre, Phase III trial of in vivo purging with anti-CD38 (Daratumumab) to enhance myeloma autografting (IPANEMA)
StatusFinished
Effective start/end date1/10/20 → 31/12/23

Funding

  • JANSSEN PHARMACEUTICA NV